Different Doses and Duration of Low Molecular Weight Heparin (Parnaparin)in Superficial Vein Thrombosis
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The optimal treatment of superficial venous thrombosis (SVT) is still uncertain. Though low
molecular weight heparin (LMWH) is considered the treatment of choice, studies conducted so
far do not give clear indications of the optimal dose and duration of treatment. This study
aims to evaluate whether an intermediate therapeutic dose of LMWH (parnaparin) is more
effective than a prophylactic dose and also to assess whether 10 rather than 30 days are
sufficient for treatment.
Phase:
Phase 3
Details
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna St. Orsola Hospital